top of page
Search

Applications of Microfluidics in mRNA Vaccine Development: A Review

The paper "Applications of Microfluidics in mRNA Vaccine Development: A Review" by Ali Fardoost and colleagues, published in Biomicrofluidics (2024), provides a comprehensive exploration of how microfluidic technologies are revolutionizing the field of mRNA vaccine development.


This review highlights the role of microfluidics in improving the efficacy, safety, and production efficiency of mRNA vaccines—advancements that have gained significant attention, especially in light of the rapid development of COVID-19 vaccines.


General overview of how mRNA vaccine works. In the first step, the mRNA-loaded LNPs should be injected into the muscle cells of the body (usually the upper arm) (1). Once mRNA-loaded LNPs enter the body (2), muscle cells and immune cells take up LNPs from the injection site (3). In the next step, inside the cells, the LNPs are broken down, releasing the mRNA into the cytoplasm (4). Ribosomes in the cytoplasm read the mRNA sequence and translate it into the target protein, such as the spike protein of the SARS-CoV-2 virus (5). The newly made viral protein (or a portion of it) is processed and presented on the cell surface (6). Finally, immune cells produce target antibodies for capturing translated protein (7). These antibodies can neutralize the virus by preventing it from infecting cells if the person is later exposed to the virus. Note that the immune system’s response to the mRNA vaccine mimics the natural infection process but without causing disease. This trains the immune system to recognize and combat the real virus if exposed.

Microfluidics and mRNA Vaccine Synergy:


Microfluidics, or the manipulation of fluids on a microscale using lab-on-a-chip devices, enhances the production and delivery of mRNA vaccines. The paper emphasizes how these devices enable more precise control over the formulation of lipid nanoparticles (LNPs), which are critical for delivering mRNA into cells. This technology allows for the rapid and cost-effective synthesis of LNPs, improving the overall production process.


  1. Advantages of Microfluidics in mRNA Vaccine Development:

    • Reduced Reagents: Microfluidic systems require significantly smaller amounts of reagents, lowering production costs.

    • Parallel Processing: The technology allows multiple samples to be processed simultaneously, increasing throughput and efficiency.

    • Enhanced Control: Microfluidics provides fine-tuned control over the mixing and formulation of vaccine components, resulting in more consistent and effective mRNA vaccines.



  2. mRNA as a Vaccine Platform:

    The review outlines the key benefits of mRNA vaccines, including their ability to induce strong immune responses without the risk of genomic integration. These vaccines are also highly adaptable, allowing for rapid updates to target emerging pathogens, such as during the COVID-19 pandemic. The authors discuss how mRNA vaccines combine the strengths of traditional live attenuated vaccines (strong immune response) with the safety of subunit vaccines (controlled composition).


    Diagram illustrating the step-by-step pharmacological mechanism of adaptive immune responses induced by mRNA–LNP vaccines. From P. K. Gote et al., Int. J. Mol. Sci. 24(3), 2700 (2023).
    Diagram illustrating the step-by-step pharmacological mechanism of adaptive immune responses induced by mRNA–LNP vaccines. From P. K. Gote et al., Int. J. Mol. Sci. 24(3), 2700 (2023).


    The in vitro transcription (IVT) reaction includes both input and output components, as well as potential impurities. From Lenk et al., Front. Mol. Biosci. 11, 1426129 (2024)
    The in vitro transcription (IVT) reaction includes both input and output components, as well as potential impurities. From Lenk et al., Front. Mol. Biosci. 11, 1426129 (2024)


  3. Microfluidic Devices in Vaccine Production:

    The review delves into the specific microfluidic devices used in mRNA vaccine research and production. Among the notable technologies is the Nanogenerator instrument from PreciGenome, which plays a crucial role in the precise formulation of LNPs. This instrument utilizes microfluidics to control the size and encapsulation efficiency of LNPs, ensuring that mRNA is effectively delivered to target cells. The Nanogenerator stands out for its ability to produce high-quality nanoparticles consistently, a key factor in the success of mRNA vaccines.

    A schematic of a microfluidic device preparing LNPs including two inlets for introducing a lipid solution, often containing lipids dissolved in ethanol or another organic solvent and an aqueous solution, often containing the therapeutic agent to be encapsulated into the microfluidic device. As a product in the outlet, we have formed LNPs with different sizes.
    A schematic of a microfluidic device preparing LNPs including two inlets for introducing a lipid solution, often containing lipids dissolved in ethanol or another organic solvent and an aqueous solution, often containing the therapeutic agent to be encapsulated into the microfluidic device. As a product in the outlet, we have formed LNPs with different sizes.

Summary of recent advances and developments in microfluidic devices for mRNA vaccine formulation.
Summary of recent advances and developments in microfluidic devices for mRNA vaccine formulation.

Future Prospects:


The paper explores the future potential of integrating microfluidics more deeply into vaccine development. As the technology evolves, it could lead to even faster vaccine production cycles, more personalized vaccine formulations, and portable devices for on-demand vaccine manufacturing, potentially transforming public health responses to pandemics and other health crises.




2 views
bottom of page